Fidelity Investments
KLDO

Fidelity Investments’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Fidelity Investments’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-6,389,660
Closed -$10.5M – 5756
2022
Q1 		$10.5M Buy
6,389,660
+508
+0% +$906 ﹤0.01% 2098
2021
Q4 		$15.3M Buy
6,389,152
+2,523
+0% +$10.3K ﹤0.01% 1946
2021
Q3 		$34.9M Buy
6,386,629
+8,832
+0.1% +$54.8K ﹤0.01% 1579
2021
Q2 		$47.5M Buy
6,377,797
+7,779
+0.1% +$55.1K ﹤0.01% 1461
2021
Q1 		$51.6M Buy
6,370,018
+2,677,459
+73% +$29.2M ﹤0.01% 1383
2020
Q4 		$33.6M Buy
3,692,559
+541,300
+17% +$4.44M ﹤0.01% 1484
2020
Q3 		$34.9M Buy
3,151,259
+436,537
+16% +$3.02M ﹤0.01% 1333
2020
Q2 		$20.2M Buy
2,714,722
+438,715
+19% +$2.94M ﹤0.01% 1545
2020
Q1 		$14M Buy
2,276,007
+189,100
+9% +$1.23M ﹤0.01% 1557
2019
Q4 		$10.5M Buy
2,086,907
+121,283
+6% +$771K ﹤0.01% 1829
2019
Q3 		$14.8M Buy
1,965,624
+40,617
+2% +$353K ﹤0.01% 1688
2019
Q2 		$21.9M Buy
1,925,007
+115,924
+6% +$1.69M ﹤0.01% 1587
2019
Q1 		$25.1M Buy
+1,809,083
New +$24.9M ﹤0.01% 1493

Other funds holding KLDO

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Fidelity Investments's KLDO Position: Q2 2022 in Review

Fidelity Investments sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2022, closing a stake of 6,389,660 shares — an estimated $10.5M sold.

Fidelity Investments first reported a position in KLDO in Q1 2019 and held it in 13 quarters. The position peaked at $51.6M in Q1 2021. 3 funds tracked by Wall St. Rank hold KLDO as of Q2 2022.

  • Fidelity Investments reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Fidelity Investments sold 6,389,660 Kaleido Biosciences, Inc. Common Stock shares in Q2 2022, an estimated $10.5M.
  • Fidelity Investments first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2019 and held it in 13 quarters.
  • Fidelity Investments's Kaleido Biosciences, Inc. Common Stock position peaked at $51.6M in Q1 2021.
  • 3 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2022.

Based on Fidelity Investments's 13F filing for Q2 2022, filed 12 Aug 2022.